Payment overview · 2025
General Payments
$1,439.79
22 reported records · 5 companies
Healthcare provider profile · identity verified
Mark Gudesblatt, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ISLIP, NY · NPI 1528030269
Verified facts
What the public records show
CMS Open Payments records show Mark Gudesblatt, M.D. received $1,439.79 in general payments during 2025 across 22 reported records.
Biogen, Inc. accounted for 56.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Tysabri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogen, Inc. | Unresolved — no canonical attribution shown | $812.64 | 56.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $333.14 | 23.1% | 13 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $168.94 | 11.7% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $83.89 | 5.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.18 | 2.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $807.00 | 1 |
| Food and Beverage | $632.79 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $213.68 | 12 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $168.94 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $60.21 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $5.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Sertraline Hcl | Sertraline Hcl | 284 | 97 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 255 | 34 |
| Donepezil Hcl | Donepezil Hcl | 214 | 68 |
| Sodium Chloride | 0.9 % Sodium Chloride | 184 | 25 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 171 | 16 |
| Bupropion Xl | Bupropion Hcl | 161 | 60 |
| Baclofen | Baclofen | 154 | 40 |
| Gabapentin | Gabapentin | 132 | 48 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 130 | 43 |
| Memantine Hcl Er | Memantine Hcl | 127 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 41 |
| Trazodone Hcl | Trazodone Hcl | 119 | 39 |
| Dalfampridine Er | Dalfampridine | 111 | 28 |
| Clonazepam | Clonazepam | 106 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 88 | 36 |
| Levetiracetam | Levetiracetam | 86 | 24 |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 82 | suppressed |
| Amantadine | Amantadine Hcl | 81 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 31 |
| Alprazolam | Alprazolam | 72 | 36 |
| Neupro | Rotigotine | 71 | 15 |
| Tysabri | Natalizumab | 67 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 65 | suppressed |
| Carbamazepine Er | Carbamazepine | 56 | 18 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 56 | 12 |
| Midodrine Hcl | Midodrine Hcl | 55 | 19 |
| Modafinil | Modafinil | 55 | 18 |
| Linzess | Linaclotide | 50 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 17 |
| Risperidone | Risperidone | 42 | 11 |
| Pregabalin | Pregabalin | 40 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 11 |
| Rasagiline Mesylate | Rasagiline Mesylate | 37 | 13 |
| Lidocaine | Lidocaine | 36 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 14 |
| Carbamazepine | Carbamazepine | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 12 |
| Diazepam | Diazepam | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Ampyra | Dalfampridine | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Scopolamine | Scopolamine | 29 | suppressed |
| Gammagard S-D | Immun Glob G/Gly/Gluc/Iga 0-50 | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | 13 |
| Famotidine | Famotidine/Pf | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | 13 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 21 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 20 | suppressed |
| Entacapone | Entacapone | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | 11 |
| Cevimeline Hcl | Cevimeline Hcl | 19 | suppressed |
| Levocarnitine | Levocarnitine | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Tegretol Xr | Carbamazepine | 19 | suppressed |
| Veozah | Fezolinetant | 19 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 18 | suppressed |
| Firdapse | Amifampridine Phosphate | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lamotrigine Er | Lamotrigine | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 14 | suppressed |
| Onpattro | Patisiran Sodium,lipid Complex | 14 | suppressed |
| Acetaminophen | Acetaminophen | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Benlysta | Belimumab | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 12 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 12 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nourianz | Istradefylline | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
| Tecfidera | Dimethyl Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,439.79 · 22 records | Biogen, Inc. | BRIUMVI, QULIPTA, UBRELVY, UPLIZNA, VUMERITY, VYVGART, VYVGART HYTRULO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error